Insurance Payer Contract Negotiation for Infectious Disease Practices

J3490 and J3590 are unclassified drug codes used when a specific drug does not have an established, applicable HCPCS code in the billing context. The distinction generally relates to the drug classification represented by the code, while payer requirements may still call for the drug name, strength, units, National Drug Code information, and supporting documentation. Practices should verify current payer billing instructions before submitting claims.

J-codes are Healthcare Common Procedure Coding System codes used to report certain drugs administered by healthcare providers. For infectious disease practices, they may be relevant to buy-and-bill drugs delivered through infusion or other treatment workflows. Accurate billing also requires attention to units, administration services, documentation, authorization, benefit classification, and payer-specific submission requirements. A contract review can show whether payment aligns with applicable terms.

Infectious disease practices may receive payment for cognitive visits, hospital consults, infusion administration, drugs, OPAT-related services, and contracted coverage work. Contract review helps determine whether those services are addressed clearly and whether actual payments align with stated terms. It can also identify provisions or omissions worth raising during renewal, particularly where clinical work is delivered under hospital or stewardship agreements.

A compliance review compares payer payment activity with the terms governing relevant services. For infectious disease practices, that may include drugs, infusion administration, consult services, fee schedules, units, NDC information, and coverage arrangements. The review can highlight payment differences, recurring application issues, and contract language that deserves clarification. Results can support internal corrections and more focused payer discussions.

Start with reporting organized by payer, service line, and provider, then compare expected contract treatment with submitted claims and actual payments. Review denials, short-pays, fee schedule application, units, drug identifiers, administration charges, and aging balances. This helps separate documentation or charge-capture issues from payer compliance concerns, giving the practice a clearer evidence base for contract renewal conversations.

Yes. Infectious disease work may be delivered through hospital coverage and stewardship agreements where compensation is not always reflected like a standard claim. Reviewing those arrangements can clarify the services being provided, the economic expectations, and whether the agreement addresses the practice’s work adequately. The analysis should distinguish contract obligations from claims-based reimbursement and identify terms that may need discussion.

Denials can reveal recurring problems with coding, authorization, medical versus pharmacy benefit classification, documentation, or payer processing. Categorizing denials by payer and root cause helps determine whether the solution is operational, contractual, or both. A documented pattern gives practices a more useful basis for discussing payer behavior, clarifying requirements, and addressing terms that create repeated reimbursement friction.

Gather the current contract and related coverage agreements, payer-level payment reports, denial categories, underpayment findings, aging accounts receivable, service-line activity, and examples involving drugs, administration, consults, or OPAT workflows. Also document internal process gaps so they are not mistaken for payer issues. Using the practice’s own numbers supports a more grounded review without relying on generalized rates or margins.